Patterns of treatment and outcomes of patients with metastatic HER2-low breast cancer treated with CDK4/6 inhibitors and hormone therapy

Federico Sottotetti, Barbara Tagliaferri, Gianpiero Rizzo, Raffaella Palumbo, Giulia Chessa, Chiara Raso, Lorenzo Perrone, Alberto Malovini, Valentina Tibollo, Laura Deborah Locati, Paolo Pedrazzoli, Angioletta Lasagna

Article Type

Original Research

Published

This study aims to investigate, through a retrospective approach and in a real-world setting, the activity and effectiveness of CDK4/6i as first-line or second-line treatment in a HR+/HER2-low population compared to matched patients with HR+/HER2-0 disease.

Read more

Real-life effectiveness of FLOT in resectable gastric cancer: existing challenges

Francesco Serra, Federica Valerio, Paolo Pedrazzoli, Jacopo Viganò, Riccardo Caccialanza, Daniela Cicognini, Anna Pagani, Salvatore Corallo

Article Type

Original Research

Published

This article aims to demonstrate the real-life effectiveness of the fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) regimen by comparing it with traditional chemotherapy regimens and aims to discover its strengths and weaknesses.

Read more

Multidisciplinary and personalized approach to the management of mycosis fungoides with chlormethine gel: a collection of clinical experiences

Silvia Alberti Violetti, Marco Ardigò, Paolo Fava, Giuseppe Gritti, Erika Morsia, Francesco Onida, Marco Paulli, Alessandro Pileri, Pietro Quaglino, Serena Rupoli, Miriam Teoli, Pamela Vezzoli

Article Type

Case Series

Published

This paper provides an overview of clinical practice evidence about the mycosis fungoides diagnostic phase and a collection of clinical experiences to better characterize the use of chlormethine gel in daily practice.

Read more

Nivolumab plus ipilimumab with chemotherapy in metastatic NSCLC: minireview and a case study of a patient negative for PD-L1

Alessandro Morabito

Article Type

Case Report

Published

This article is a minireview on the evolutionary course of non-small-cell lung cancer treatment over recent years, and discusses a case involving a patient who tested negative for PD-L1 but experienced a sustained complete response to explore strategies for addressing this specific tumour context.

Read more

Register for alerts

I would like to be contacted by Drugs in Context when new articles are posted.